The following stories appear in full on Today's Vidyya Medical News Service Web site.
The National Cancer Institute's (NCI) Division of Cancer Prevention is studying the drug celecoxib (Celebrex) for the prevention of cancer in people with precancerous conditions and in people at high risk for second cancers. Celecoxib inhibits the body's production of an enzyme known as cyclooxygenase-2 (COX-2), which helps control inflammation. In fact, celecoxib was approved by the U.S. Food and Drug Administration (FDA) for the treatment of both osteoarthritis and adult rheumatoid arthritis (diseases in which the joints are inflamed) in December 1998.
For more information: NCI-Sponsored Trials Of Celecoxib For Cancer Prevention
Three articles in the Feb. 21 issue of the Journal of the National Cancer Institute focus on the causal relationship between human papillomavirus (HPV) and cervical cancer and its implications for prevention efforts. The articles present results from a randomized, controlled study of a vaccine against HPV type 16 (HPV16), which is found in about half of cervical cancers; from a multicenter, randomized trial that examines the role of HPV testing in women with equivocal cytologic abnormalities; and from a case–control study of the cervical cancer risk associated with different variants of HPV16.
For more information: Studies Expand On Relationship Between Human Papillomavirus And Cervical Cancer
The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure is an update of the previous guideline
and contains important new information for clinicians. The JNC VI was developed using evidence-based medicine and consensus to make recommendations to clinicians. As an update, it provides a contemporary approach to hypertension prevention and control. New information since JNC V includes data from phase 2 of the third National Health and Nutrition Examination Survey, updated information on the year 2000 objectives for the nation, a discussion of new pharmacologic therapies including combination drugs, the role of managed care in the treatment of high blood pressure, and information from recently completed randomized controlled trials on hypertension prevention and treatment.
For more information: The Sixth Report Of The Joint National Committee On Prevention, Detection, Evaluation, And
Treatment Of High Blood Pressure
National dietary recommendations have consistently included qualitative recommendations for salt/sodium since the 1970s. Since then scientific evidence has continued to accumulate. The workshop summarized in this paper in today's Vidyya, Implementing Recommendations for Dietary Salt Reduction, was predicated on a scientific perspective and proceeded with certain assumptions based on conclusions of the National Heart, Lung, and Blood Institute (NHLBI) Workshop on Salt and Blood Pressure.
For more information: Implementing Recommendations For Dietary Salt Reduction
We are happy to include the recommendations for measuring LDL-cholesterol, HDL-cholesterol, and triglycerides from the National Cholesterol Education Program appear in today's issue. Separate sections of this report are devoted to each type of measurement and feature an executive summary, background information, a discussion of major issues, recommendations, and references. This comprehensive reference book includes recommendations for manufacturers, health care providers, laboratories, and government agencies and other professional groups.
For more information: Recommendations On Lipoprotein Measurement
Today's Vidyya articles are:
As always, we hope you enjoy the issue.